179899-22-0

Basic information

• Product Name: 2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine
• Synonyms: 2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine;7-aMino-1,2,3,4-tetrahydro-2,2-diMethylquinoline;2,2-diMethyl-1,2,3,4-tetrahydro-quinolin-7-ylaMine
• CAS NO: 179899-22-0
• Molecular Formula: C11H16N2
• Molecular Weight: 176.25814
• Mol File: 179899-22-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine(179899-22-0)
• EPA Substance Registry System: 2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine(179899-22-0)

Safety Data

• Hazardous Substances Data: 179899-22-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and potential biological activities make it a valuable component in the development of new drugs and treatments.
Used in Organic Synthesis:
2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine is used as an intermediate in organic synthesis, allowing for the creation of a wide range of chemical compounds. Its versatility and reactivity make it a useful tool in the synthesis of various organic molecules.
Used in Research and Development:
2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine is used in research and development applications, where its potential biological activities and unique structure are further investigated. This can lead to the discovery of new applications and uses for 2,2-DiMethyl-1,2,3,4-tetrahydroquinolin-7-aMine in various fields, including medicinal chemistry.

Upstream product

• 201541-36-8 1,2,3,4-tetrahydro-2,2-dimethyl-7-nitroquinoline 
• 14465-61-3 2,2-dimethyl-1,2-dihydroquinoline 
• 7471-09-2 3-methyl-3-phenylamino-1-butyne 
• 121-14-2 2,4-dinitrotoluene 
• 179898-87-4 1-tert-butoxycarbonyl-1,2,3,4-tetrahydro-2,2-dimethyl-4-quinolinone 
• 132588-91-1 1,2,3,4-tetrahydro-2,2-dimethylquinolin-4-one 
• 20364-30-1 2,2-dimethyl-1,2,3,4-tetrahydroquinoline 

Relevant articles and documents

1,2,3,4-tetrahydroquinoline compound and synthetic method and application thereof

The invention relates to 1,2,3,4-tetrahydroquinoline compound and a synthetic method and application thereof. In a structure formula of the compound, the R1 is nitro or trifluoromethyl or 3-nitrophenylnitrobenzene sulfonyl or cyano, the R2 is hydrogen or methyl, the R3 is methyl formate or butyl formate, and the R4 is methyl. An aromatic ring of the 1,2,3,4-tetrahydroquinoline compound contains a series of electron withdrawing groups. The synthetic method is simple, economical, environment-friendly, easy to operate, easy to control, higher in product purity and yield and good in development prospect in industrial production; in addition, the synthetic method is also a novel synthetic method in atom economy; furthermore, the 1,2,3,4-tetrahydroquinoline compound can serve as intermediate to be used for preparing antagonist medicine.

Androgen receptor modulator compounds and methods

Non-steroidal compounds that are high affinity, high selectivity modulators for androgen receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring androgen receptor agonist, partial agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the androgen receptor modulator compounds.

Switching Androgen Receptor Antagonists to Agonists by Modifying C-Ring Substituents on Piperidinoquinolinone

New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H-piperidinoquinolinone. (+/-)-trans-7,8-diethyl-4-trifluoromethyl-2(1H)-piperidinoquinolinone was synthesized and demonstrated p

Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2- dihydropyridono[5,6-g]quinolines

A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR- mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure - activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.

Tricyclic steroid receptor modulator compounds and methods

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

Steroid receptor modulator compounds and methods

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS

Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.